EIGR - Eiger BioPharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.55
-0.40 (-3.09%)
As of 10:32AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close12.95
Open12.99
Bid12.55 x 1000
Ask12.70 x 400
Day's Range12.55 - 12.99
52 Week Range6.10 - 13.95
Volume4,308
Avg. Volume60,781
Market Cap131.981M
Beta1.98
PE Ratio (TTM)N/A
EPS (TTM)-5.30
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.67
Trade prices are not sourced from all markets
  • PR Newswire28 days ago

    Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference

    PALO ALTO, Calif., Nov. 13, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate update at Jefferies 2017 Healthcare Conference on Thursday, November 16, 2017 at 4:40 pm CET at the Waldorf Hilton London in the Westminster Room on the Entresol Level.  Eiger will also host one-on-one meetings. Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases.  We are committed to translational innovation and the repurposing of well-characterized drugs acting on newly identified or novel targets.  Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with orphan diseases.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

  • Associated Presslast month

    Eiger BioPharma reports 3Q loss

    The Palo Alto, California-based company said it had a loss of $1.10 per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • PR Newswirelast month

    Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results

    -Clinical Results Planned in Each of Four Orphan Disease Programs by 4Q 2018 -Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , Nov. 9, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: ...

  • Should Your Next Investment In The Healthcare Industry Be In Eiger BioPharmaceuticals Inc (EIGR)?
    Simply Wall St.last month

    Should Your Next Investment In The Healthcare Industry Be In Eiger BioPharmaceuticals Inc (EIGR)?

    Eiger BioPharmaceuticals Inc (NASDAQ:EIGR), a USD$118.65M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...

  • Does Eiger BioPharmaceuticals Inc’s (EIGR) Debt Level Pose A Serious Problem?
    Simply Wall St.last month

    Does Eiger BioPharmaceuticals Inc’s (EIGR) Debt Level Pose A Serious Problem?

    While small-cap stocks, such as Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) with its market cap of USD $119.70M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • PR Newswirelast month

    Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock

    PALO ALTO, Calif., Oct. 27, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of 1,854,749 shares of its common stock at a price of $10.00 per share, before underwriting discounts and commissions.  All of the shares of common stock to be sold in the offering are to be sold by Eiger.  In addition, Eiger has granted to the underwriter a 30-day option to purchase up to 278,212 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

  • PR Newswire2 months ago

    Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

    PALO ALTO, Calif., Oct. 26, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  Eiger intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.  All of the shares of common stock to be sold in the offering will be offered by Eiger.  There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BTIG, LLC is acting as sole book-running manager for the offering.

  • PR Newswire2 months ago

    Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting

    PALO ALTO, Calif. , Oct. 23, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive interim 24-week data with pegylated interferon lambda (Lambda) in the Phase 2 LIMT ...

  • PR Newswire2 months ago

    Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting

    PALO ALTO, Calif. , Oct. 2, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that two abstracts will be presented at the American Association for the Study of Liver Diseases ...

  • PR Newswire3 months ago

    Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors

    PALO ALTO, Calif., Sept. 18, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh, MD to its Board of Directors.  Dr. Loh's clinical development and regulatory experience spans nearly two decades across all phases of development ranging from discovery to registration, across multiple therapeutic areas including oncology, infectious diseases, inflammation and rare diseases.  The company concurrently announced that Ed Engleman, MD, Managing Partner at Vivo Capital and a founding venture investor, is departing from the Board.

  • PR Newswire3 months ago

    Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

    PALO ALTO, Calif., Sept. 5, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan designation for pegylated interferon lambda 1a (Lambda) as a potential treatment for chronic hepatitis delta virus (HDV) infection.

  • PR Newswire3 months ago

    Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences

    PALO ALTO, Calif. , Aug. 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today ...

  • Associated Press4 months ago

    Eiger BioPharma reports 2Q loss

    On a per-share basis, the Palo Alto, California-based company said it had a loss of $1.33. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • PR Newswire4 months ago

    Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results

    - Five Phase 2 Programs Advancing in Multiple Orphan Indications - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif. , Aug. 14, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, ...

  • PR Newswire4 months ago

    Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th

    Eiger will also host one-on-one meetings with investors at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017. Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases.

  • PR Newswire5 months ago

    Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

    PALO ALTO, Calif., July 27, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for pegylated interferon lambda 1a (Lambda) as a potential treatment for chronic hepatitis delta virus (HDV) infection. The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.  Through the Fast Track program, a product may be eligible for priority review at the time of submission of a New Drug Application (NDA) or Biological License Application (BLA) and may also be eligible to submit completed application sections on a rolling basis.  These expedited processes can significantly reduce development and application review time and costs associated with bringing a drug to market.

  • PR Newswire5 months ago

    Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

    PALO ALTO, Calif., July 24, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced completion of enrollment of the Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in HDV) Study, a monotherapy trial of pegylated interferon lambda 1a ("Lambda") as a potential treatment for chronic hepatitis D virus (HDV) infection. LIMT HDV is designed to evaluate the safety, tolerability and efficacy of two dose levels of weekly subcutanoues injections of Lambda after 48 weeks of treatment. LIMT HDV is an international study with clinical sites in New Zealand, Israel and Pakistan. A total of thirty-three patients were enrolled.

  • Zacks5 months ago

    Eiger BioPharmaceuticals (EIGR) Rises: Stock Climbs 24%

    Eiger BioPharmaceuticals, Inc. (EIGR) shares rose over 24% in the last trading session.

  • PR Newswire5 months ago

    Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals

    PALO ALTO , Calif. and SAN DIEGO , June 29, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), announced today an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology ...

  • PR Newswire6 months ago

    Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors

    PALO ALTO, Calif., June 14, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, PhD, MBA to its Board of Directors.  Dr. Apelian's clinical development and regulatory experience spans 17 years in all phases of development ranging from discovery to registration, across multiple therapeutic areas including GI, hepatology, immuno-oncology, infectious diseases, and rare diseases.  The company concurrently announced that Nina Kjellson, founding venture investor, is departing from the Board.

  • PR Newswire6 months ago

    Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego

    PALO ALTO, Calif., June 12, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced positive ...

  • PR Newswire6 months ago

    Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients

    PALO ALTO, Calif., June 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced completion ...

  • PR Newswire6 months ago

    Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th

    Eiger will also host one-on-one meetings with investors at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017. Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases.

  • PR Newswire7 months ago

    Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema

    PALO ALTO, Calif., May 17, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies ...

  • PR Newswire7 months ago

    Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

    PALO ALTO, Calif., May 15, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion ...